Abstract / Summary
Purpose: How sarcoma subtypes engage telomerase versus alternative lengthening of telomeres (ALT), and with what consequence, is incompletely defined. Methods: We analyzed 11,792 patients with sarcoma sequenced across 19 centers in AACR Project GENIE v20.0. Telomerase activation was defined as TERT promoter mutation, amplification, or rearrangement, and ATRX/DAXX inactivation served as the ALT proxy, each assessed only where the assay interrogated the locus. Findings were tested for TERT expression in The Cancer Genome Atlas (TCGA), for overall survival (OS) in MSK-IMPACT 50K, and for replication in an independent Foundation Medicine cohort. Mendelian randomization (MR) in FinnGen tested germline telomere length. Results: Telomerase activation (8.8%) and ATRX/DAXX loss (8.0%) were mutually exclusive across subtypes (odds ratio [OR], 0.52; 95% CI, 0.29 to 0.92) and segregated by histology. In MDM2-amplified dedifferentiated liposarcoma (DDLPS), telomerase was activated through TERT amplification (17.2%) or rearrangement (2.7%), never promoter mutation (0/261), and never with ATRX/DAXX loss (0/49; P = .011). TERT-amplified tumors expressed TERT (TCGA; P = .002), and amplification was largely focal. Telomere maintenance alterations were present in 28.0% of DDLPS versus 8.7% of well-differentiated liposarcoma (P < .001) and predicted shorter OS in DDLPS (hazard ratio, 2.04; 95% CI, 1.23 to 3.39; P = .005). ATRX/DAXX loss was more frequent in uterine than extrauterine leiomyosarcoma in GENIE (adjusted OR, 1.96) and in the independent cohort (OR, 1.95; both P < .001). Genetically longer telomeres were associated with liposarcoma (OR per SD, 4.10; 95% CI, 2.15 to 7.81). Conclusion: Sarcoma telomere maintenance is histology-specific and mutually exclusive. In liposarcoma it is acquired at dedifferentiation through focal TERT amplification or ALT and identifies DDLPS with inferior survival.